A method was developed and validated for determination and quantitation of tilmicosin residues in swine, cattle, and sheep edible tissues, as well as chicken fat, skin, and muscle over a concentration range of 0.025 mg/g-20 mg/g. For chicken kidney and liver, the method was validated over a range of 0.060 mg/g-20 mg/g. The tissue sample was extracted with methanol and a C 18 cartridge was used for solid-phase extraction cleanup. A reversedphase gradient liquid chromatographic method with detection at 280 nm was used to separate the tilmicosin from matrix components in 30 min run time. The limit of quantitation (LOQ) of the method was 0.025 mg/g for all tested tissues except chicken kidney and liver, for which the LOQ was 0.06 mg/g. Average recoveries for tissue samples ranged from 73 to 98%. Relative standard deviation values ranged from 0.6 to 14.7%.
T ilmicosin (20-deoxo-20-(3,5-dimethyl-piperidin-1-yl)-desmycosin is a semisynthetic macrolide antibiotic (1) with a spectrum of microbiological activity against Pasteurella spp., Mycoplasma spp., and a variety of Gram-positive organisms (2) . Figure 1 shows the structure of tilmicosin. Tilmicosin is composed of cis and trans piperidinyl isomers in a ratio of about 85:15%. A bovine injection formulation of tilmicosin (Micotil ® , Eli Lilly and Co., Greenfield, IN) has been approved in several countries for the treatment of bovine respiratory disease caused by Pasteurella haemolytica (3) (4) (5) . Micotil is also approved in some countries outside the United States for use in sheep. A type A medicated article (premix) formulation of tilmicosin (Pulmotil ® , Eli Lilly and Co.) has been developed as a feed additive for control of porcine bacterial pneumonia caused by Actinobacillus pleuropneumoniae and Pasteurella multocida.
A method for tilmicosin in cattle and swine muscle and kidney (6) was previously reported. The method presented here has greater specificity for tilmicosin with regard to matrix components, and is appropriate for use with the following matrixes for which tilmicosin residue methods have not been published: cattle and swine liver and fat; chicken kidney, liver, abdominal fat, skin, and muscle; and sheep kidney, liver, fat, and muscle. The chromatographic conditions of the current method are also specific for tilmicosin metabolites and a wide variety of veterinary drugs (7) . This method uses extraction and cleanup conditions similar to the previous method (6) , and chromatographic conditions from a previously published tilmicosin feed method (7) . It is validated for chicken, swine, cattle, and sheep edible tissues with respect to linearity, accuracy, precision, sensitivity, and specificity. 
METHOD

Reagents
Standard Preparation
Perform these steps under conditions to protect from bright light.
(a) Dried tilmicosin reference standard.-Obtain at least 50 mg tilmicosin reference standard and place in actinic glass bottle. Remove lid and cover mouth of bottle with piece of filter paper secured with rubber band. Place in vacuum oven at 60 ± 5°C and at gauge pressure of at least 26 in. mercury (660 mm Hg) for at least 3 h. Remove reference standard from oven and let cool to room temperature in a desiccator (ca 30 min). Dry tilmicosin reference standard immediately before use in preparing stock standard solution. (Caution: Tilmicosin reference standard should be used only in chemical fume hood or ventilated balance enclosure with appropriate eye protection, impervious gloves, and lab coat.) (b) 250 mg/mL stock standard solution.-Accurately weigh amount of dried tilmicosin reference standard equivalent to ca 25 mg when compensated for purity and transfer to 100 mL volumetric flask. Dissolve and dilute to volume with methanol. Stopper flask tightly and wrap with aluminum foil to minimize light-induced degradation. Tilmicosin standard solutions of this concentration are stable when stored at 4 ± 4°C in a light-protected environment for 3 months. Discard unused portion of dried reference standard. (Caution: Tilmicosin reference standard should only be used in a chemical fume hood or ventilated balance enclosure with appropriate eye protection, impervious gloves, and lab coat.) (c) 10 mg/mL fortifying standard solution.-Remove 250 µg/mL stock standard solution from refrigerator and let warm to room temperature. Pipet 1 ± 0.05 mL 250 µg/mL stock standard solution into 25 mL volumetric flask and dilute to volume with MeOH. This fortifying standard solution (concentration 10 µg/mL) will be used to fortify the standard recovery sample. Use actual concentration for stock standard in calculating concentration of fortification standard. This solution is stable when stored in a light-protected environment for 7 days at either room temperature or 4 ± 4°C.
(d) 0.05, 0.25, 0.5, 2.5, and 5.0 mg/mL working standard solutions.-Using volumetric pipets and flasks, dilute with 5% acetic acid in methanol as outlined in Table 1 . Use actual concentration for stock standard in calculating the concentration of working standards. Tilmicosin standard solutions of these concentrations are stable when stored in a light-protected environment for 7 days at refrigerated temperature (ca 5°C) or at room temperature.
Sample Storage and Homogenization
Store all test tissues at freezer temperatures (ca -20°C) until they are processed. Homogenize each test tissue separately by using a food grinder or chopper unless tissue sizes are so small that a substantial amount could be lost in the grinder. In this case, homogenize test tissues by mincing and chopping with a scalpel, scissors, or mortar and pestle, instead of using the food grinder.
Preparation of Recovery and Negative Control Samples
On the day of analysis, prepare one recovery sample of one of the tissue types to be analyzed. Fortify untreated control tissue with 10.0 µg/mL fortifying standard solution to obtain 1 µg/g sample. Fortify at rate of 0.5 mL solution per 5 g tissue. Perform fortification with 0.5 mL volumetric pipet or micropipettor. Include an untreated (negative) control tissue sample of one of the tissue types to be analyzed with each set of treated samples.
Sample Preparation Before Solid-Phase Extraction
Perform all steps from this point on under conditions to protect from bright light. Defrost tissue at room temperature. Weigh, to nearest 0.01 g, 4.50-5.50 g of a representative homogeneous tissue sample into 50 mL disposable centrifuge tube. Add 10 ± 1 mL methanol to the sample and sonicate using ultrasonic probe for ca 15-30 s or until sample is sufficiently uniform. Take care not to overheat sample during sonication at this step; sample should become only slightly warm to the touch. Centrifuge at 2000 rpm for 10 min. Exact speed, centrifugal force, size, or spin time is not critical and may be adjusted, provided sample is sedimented to give clear supernatant. Decant supernatant into appropriately sized flask and set aside. Add 5 ± 1 mL 100mM pH 2.5 phosphate buffer and 10 ± 1 mL methanol to centrifuge tube and completely resuspend packed tissue by stirring vigorously with spatula or wooden stick. Sample may also be shaken or Vortex mixed if desired. Centrifuge again as before. Leave supernatant in centrifuge tube. Shortly before applying sample to solid-phase extraction cartridge, add 70 ± 2 mL water to the first methanol extract in its flask. Add the second methanol-buffer extract to the mix, and swirl flask briefly.
Solid Phase Extraction and Final Sample Preparation
Place SPE cartridge into vacuum manifold system with SPE cartridge effluent going to a solvent trap. Condition SPE cartridge with ca 10 mL methanol, and then ca 10 mL water. Flow rate is not important for these steps. Apply sample to cartridge. A flow rate of up to 8 mL/min may be used.
Following application of sample extract to SPE cartridge, apply ca 10 mL water as interference elution solvent. Flow rate is not important for this step. Then apply ca 10 mL 25% acetonitrile in water no faster than ca 5 mL/min.
After the 25% acetonitrile in water has drained from the SPE cartridge, let SPE cartridge dry at high vacuum (at least 5 in./130 mm Hg) for at least 3 min. Once SPE cartridge has been dried, turn off vacuum and elute tilmicosin with 5% glacial acetic acid in methanol. To do this, fill a small syringe with ca 3 mL elution solution. Remove SPE cartridge from manifold and connect it to the syringe. Hold outlet of SPE cartridge over mouth of 2 mL volumetric flask and slowly depress plunger on syringe to push eluent through the cartridge. Collect eluent in flask until liquid level just reaches volume marker. (Not all of the elution solution in the syringe is needed to elute to the 2 mL mark.) The resulting sample may be colored or cloudy. Stopper the flask and invert it several times to mix the sample. Filter the sample with a 0.45 µm PTFE filter into an LC autosampler vial for assay. These extracts are stable for at least 7 days when stored at room temperature in light-protected environment.
Liquid Chromatography 100% acetonitrile at 2 mL/min; followed by flushing for 30 min with 100% water at 2 mL/min. Wavelength, 280 nm; flow rate, 1.5 mL/min; injection volume, 100 µL; column temperature, ambient; run time, 30 min; mobile phase A, ACN; mobile phase B, H 2 O; mobile phase C, 0.02M DBAP solution; gradient conditions, see Table 2 .
Presamples.-At least one methanol injection should be used to equilibrate column to gradient conditions.
Initial instrument set-up.-The 0.02M DBAP solution can desorb compounds previously trapped in the system or column, producing a large shift in the baseline after 0.02M DBAP solution is introduced. To correct this phenomenon, flush system and column with mobile phase that is 25% acetonitrile and 75% 0.02M DBAP, or repeat gradient cycle until satisfactory baseline is obtained.
Column storage.-On short-or long-term basis, the column can be stored with acetonitrile-water (1 + 1).
(b) System suitability.-System suitability should be checked at least daily or when any significant changes are made to the instrument set-up.
As a test of system suitability, observe retention time of tilmicosin peak in 100 µL injection of one of the standard curve solutions. To be acceptable, retention time of the tilmicosin peak must fall in the range of 13-19 min. When tilmicosin peak is eluted in the 13-19 min range, it is free of interference from sample matrix, related substances, degradation products, and other potential interfering compounds. Figure 2 shows an example chromatogram of a tilmicosin standard.
As a corrective action to system suitability failure, the 5-25 min gradient conditions should be modified to move tilmicosin to an appropriate retention time (13-19 min). Tilmicosin is strongly adsorbed to residual silanols; therefore, the amine modifier (0.02M DBAP) is necessary to displace tilmicosin from residual silanols. The retention time of tilmicosin may be shortened or lengthened by increasing or decreasing the amount of acetonitrile in the 5-25 min time window (7) .
The column and chromatographic conditions were chosen to elute both cis and trans isomers of tilmicosin as a single peak. With some columns, peak broadening, fronting, or tailing may be observed. If the same distortion in peak shape is observed in both standard and sample peaks, and the tilmicosin peaks can be appropriately integrated, quantitation is not precluded. To correct peak distortion, a new column is usually required.
(c) Analysis procedure.-Inject 100 µL tilmicosin system suitability standard and adjust gradient, if necessary, as described above. Next, inject 100 µL working standard solutions (5.0, 2.5, 0.50, 0.25, 0.05 µg/mL), followed by 100 µL injections of control sample, recovery sample, and samples for analysis. Finally, inject additional 100 µL injection of each working standard solution. (Note: If >30 samples are included, run a third standard curve in the middle of the run.)
Calculations
Integrate the area of the tilmicosin peak for standards and samples. All standard injections, both before and after samples, should be used in linear regression calculations. However, for a lengthy run using 3 or more sets of standard curve solutions, the analyst may calculate results for a set of samples using only bracketing curves. This is a preferred approach if the LC system sensitivity or peak retention time has drifted significantly during the course of a lengthy run. When the linear response of the standard curve is calculated over the entire standard curve concentration range, deviations from linearity at the lowest levels begin to occur. Therefore, it is better to use 2 standard curves, one over the range of 0.05-0.50 µg/mL and the other over the range of 0.50-5.0 µg/mL for tissue samples. 
where A = area of tilmicosin peak from chromatogram; B = intercept of standard curve; C = slope of standard curve; D = final volume of sample extract (2.0 mL); E = dilution factor (mL dilution volume/mL sample extract; this factor is used only when high concentration sample extracts are diluted and reassayed by LC as described below); F = weight of tissue (5 g); G = purity of tilmicosin reference standard. (Note: Factor G may not be necessary if purity of tilmicosin standard is accounted for when the standard is prepared or by the computer system used for the calculation.) Report concentrations to 3 significant figures.
If concentration of tilmicosin in samples is greater than the high point on the standard curve, make an appropriate dilution of the sample using a micropipettor and the sample diluent. Reassay the sample by LC. The value generated by the reassay is the final result for that sample.
If the concentration of tilmicosin in the samples is less than the limit of quantitation (LOQ) for the method, the sample results will be reported as such (i.e., <0.06 µg/g for chicken kidney and liver, and <0.025 µg/g for all other tissues).
( 
Results and Discussion
Validation data for the method were collected with respect to linearity, accuracy, precision, sensitivity, and specificity.
Method linearity was determined by preparing 5 solutions of tilmicosin reference standard, in duplicate, over the concentration range of 0.05-5.0 µg/mL. In practice, linearity is not acceptable when such a large concentration range of standards is used. Alternatively, 2 standard curves were used: One ranging from 0.05 to 0.5 µg/mL, and the other from 0.5 to 5.0 µg/mL. When the standard curve was split, a linear response in both sections of the curve was generated. The slope, intercept, correlation coefficient, and percent relative standard deviation (%RSD) for the standard curve ranging from 0.05 to 0.50 µg/mL were 35.71, 0.16, 0.9990, and 3.7%, respectively. The slope intercept, correlation coefficient and %RSD for the standard curve ranging from 0.50 to 5.0 µg/g were 39.90, -1.36, 1.0000, and 0.7%, respectively. Therefore, the linearity of the method is acceptable.
Method accuracy and precision for the tissue method were investigated by assaying 2 replicates of each tissue type from each species at 0.025, 0.05, and 1.0 µg/g for 3 days by a single analyst. (An exception was cattle fat, which was assayed only for 1 day because the amount of control tissue available was limited.) Chicken kidney and liver were also investigated at the 0.06 µg/g concentration level. The average concentration, %RSD, and percent recovery from each day of analysis at each tissue type, species, and concentration level are summarized in Tables 3-6 . The acceptance criterion for method accuracy was an average recovery between 70 and 110% for each group of samples. This criterion was met for fortified tissue samples at all concentrations. The acceptance criterion for method precision was an RSD of 15% or less for each group of samples. This criterion was met for fortified tissue samples at all concentrations, except at the 0.025 and 0.50 µg/g levels for chicken kidney and liver, where the RSD exceeded 15%. However, criteria for percent recovery and %RSD were met for chicken kidney and liver at the next highest concentration tested, 0.06 µg/g. Thus, the LOQ for all tissue except chicken kidney and liver is 0.025 µg/g; the LOQ for chicken kidney and liver is 0.06 µg/g. The highest fortification level tested in tissues was 1.0 µg/g. To extend the assayable concentration range of the method to 20 µg/g, precision and accuracy data for samples of higher concentration were required. Three liver samples from each species were fortified at a 20 µg/g level and assayed. (Liver was chosen because, for incurred tissue from these 4 species, it always has the highest residue levels of tilmicosin [8] .) The resulting extracts were diluted with sample elution solution to be in the concentration range of the standard curve and assayed by LC. The percent recovery and %RSD results were comparable to those of the other concentrations tested, extending the range of this method for tissues to 20 µg/g (Tables [3] [4] [5] [6] .
No significant interferences were observed around the retention time of tilmicosin in any of the control chicken, swine, cattle, or sheep tissues tested. Control tissue was taken from male and female animals, and tested for the presence of any interfering matrix peaks. Figure 2 shows representative chromatograms of a tilmicosin standard and control kidney and liver samples from chicken and sheep. (Kidney and liver are shown because they generally have the most matrix peaks). Figure 3 shows representative chromatograms of a tilmicosin standard and control kidney and liver samples from swine and cattle. Figure 4 shows the specificity of this method for tilmicosin versus tilmicosin metabolites T-1 (N-desmethyl tilmicosin), T-9 (tilmicosin devoid of the mycinose moiety), and T-10 (N-desmethyl tilmicosin devoid of the mycinose moiety).
Eighteen potential interferences (tylosin, avilamycin, avoparcin, olaquindox, ractopamine, salinomycin, apramycin, monensin, narasin, nicarbazin, bambermycin, zinc bacitracin, carbadox, chlortetracycline, hygromycin B, lincomycin, oxytetracycline, and virginiamycin) were previously tested using the LC parameters in this method (7) . This chromatographic method offers a greater specificity for tilmicosin than previously reported residue methods for tissue and milk (6, 9).
The limit of detection (LOD) for the method was determined separately for each species by measuring the peak height of that species' control tissue samples. After these data were examined, 2 separate LODs were computed for chicken: one for liver and kidney, and the other for abdominal fat, skin, and muscle, because of the greater matrix interference in chicken kidney and liver. The greater background matrix raises the LOD. (Swine, cattle, and sheep kidney and liver results did not have this problem.) The LOD was defined as the concentration of standard that corresponded to the average peak height of the control samples plus 3 times the standard deviation of the peak height. The LOD was calculated to be 0.013 µg/g for chicken kidney and liver; 0.0053 µg/g for chicken abdominal fat, skin, and muscle; 0.0066 µg/g for swine tissue; 0.0075 µg/g for cattle tissue; and 0.011 µg/g for sheep tissue. Stability of fortification solutions, standard curve solutions, final LC sample extracts, and tilmicosin in tissue matrixes was investigated. The fortification and standard curve solutions were stable for at least 7 days at room temperature. LC sample extracts from each tissue type and each species were stable for at least 7 days at room temperature. The stability of tilmicosin in the tissue matrixes was tested by storing previously fortified samples at -20 ± 12°C and removing them for assay at the appropriate time. When stored at -20 ± 12°C, chicken tissues were stable for at least 8 weeks; cattle kidney, liver, and muscle for at least 4 weeks; swine tissue for at least 10 weeks; and sheep fat and muscle for at least 33 days. Tilmicosin in sheep kidney and liver degraded more rapidly; it was stable in these tissues for 7 days.
Ruggedness of the LC portion of this method was previously proven by extensive use of this chromatography. This chromatography is identical to that used in a previously published feed method (7), which was validated in an interlaboratory study (10) .
Conclusions
The tissue method presented is suitable for determination of tilmicosin in swine, cattle, and sheep edible tissues, and for chicken abdominal fat, skin, and muscle over a concentration range of 0.025-20 µg/g. In chicken kidney and liver, the method is validated over the range of 0.06-20 µg/g. The method was tested with fortified tissue samples, and has adequate precision (RSD 0.6-14.7%) and recovery (73-98%). The method is specific with respect to tissue matrixes, tilmicosin-related substances and degradation products, and other potential interfering drugs. Finally, the method is demonstrably rugged and reliable. This unique 4-species tissue validation effort involved the work of 4 analysts using 4 different columns and chromatographic set-ups.
